GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Total Inventories

ChemoCentryx (ChemoCentryx) Total Inventories : $5.47 Mil (As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Total Inventories?

ChemoCentryx's total inventories for the quarter that ended in Jun. 2022 was $5.47 Mil. ChemoCentryx's average total inventories from the quarter that ended in Mar. 2022 to the quarter that ended in Jun. 2022 was $4.19 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ChemoCentryx's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was $2.13.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ChemoCentryx's Days Inventory for the three months ended in Jun. 2022 was 475.63.

Inventory Turnover measures how fast the company turns over its inventory within a year. ChemoCentryx's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.19.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ChemoCentryx's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 0.36.


ChemoCentryx Total Inventories Historical Data

The historical data trend for ChemoCentryx's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Total Inventories Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.85

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.85 2.90 5.47

ChemoCentryx Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


ChemoCentryx  (NAS:CCXI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ChemoCentryx's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is

Net-Net Working Capital Per Share (Q: Jun. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(328.615+0.75 * 4.946+0.5 * 5.474-182.86
-0-0)/71.3448
=2.13

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ChemoCentryx's Days Inventory for the three months ended in Jun. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2022 )/Cost of Goods Sold (Q: Jun. 2022 )*Days in Period
=4.1855/0.803*365 / 4
=475.63

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ChemoCentryx's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2022 ) / Average Total Inventories (Q: Jun. 2022 )
=0.803 / 4.1855
=0.19

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ChemoCentryx's Inventory to Revenue for the quarter that ended in Jun. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=4.1855 / 11.763
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


ChemoCentryx Total Inventories Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027

ChemoCentryx (ChemoCentryx) Headlines